by NEXT STEPS IN DERM TEAM on June 5, 2020June 29, 2020
The patient developed this cutaneous adverse event 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication? A. Epidermal growth factor receptor (EGFR) inhibitor B. Tumor necrosis factor (TNF)-alpha inhibitor C. Smoothened inhibitor D. BRAF inhibitor E. Programmed cell death (PD)-1 inhibitor To find out the correct answer and …

Continue reading "Clinical Trial – Friday Pop Quiz 6/5"